Back to Search

CRAIG BUNNELL, MD

MD

Medical Oncology Physician

NPI: 1982679767IndividualAccepts Medicare

Specialties, Licenses & Credentials

Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

75976(MA)

CMS Specialties

PrimaryMEDICAL ONCOLOGY

Additional

INTERNAL MEDICINE

Education

HARVARD MEDICAL SCHOOL

Class of 1990

Research & Publications (20)

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
PMID 18650153·Clin Breast Cancer·2008
3-trial
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.
PMID 11761451·Cancer Chemother Pharmacol·2001
3-trial
Current perspectives for treatment of breast cancer.
PMID 11114868·Breast Cancer·2000
6-review
Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations.
PMID 17879984·J Pharm Sci·2008
8-other
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
PMID 17606975·J Clin Oncol·2007
3-trial
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
PMID 17606972·J Clin Oncol·2007
3-trial
Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer.
PMID 19442346·J Soc Integr Oncol·2006
2-rct
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
PMID 16243442·Int J Radiat Oncol Biol Phys·2006
3-trial
Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.
PMID 16184455·Breast Cancer Res Treat·2005
8-other
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.
PMID 16293876·J Clin Oncol·2005
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
44 BINNEY ST, DANA-FARBER CANCER INSTITUTE
BOSTON, MA 02115

Quick Facts

NPI
1982679767
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
36
Publications
20

Are you this provider?

Claim Your Profile